Inhaled beta-2 agonist salbutamol and acute lung injury: An association with improvement in acute lung injury

Title: Inhaled beta-2 agonist salbutamol and acute lung injury: An association with improvement in acute lung injury
Authors: Manocha, S
Gordon, AC
Salehifar, E
Groshaus, H
Walley, KR
Russell, JA
Item Type: Journal Article
Abstract: Introduction β2 agonists have several properties that could be beneficial in acute lung injury (ALI). We therefore chose to study the effect of inhaled β2 agonist use (salbutamol) on duration and severity of ALI. Methods We undertook a retrospective chart review of 86 consecutive mechanically ventilated patients with ALI, who had varying exposure to inhaled salbutamol. The cohort was divided into two groups according to the average daily dose of inhaled salbutamol they received ('high dose' ≥ 2.2 mg/day and 'low dose' <2.2 mg/day). Severity of ALI and non-pulmonary organ dysfunction was compared between the groups by calculating the days alive and free of ALI and other organ dysfunctions. Results The high dose and low dose groups received a mean of 3.72 mg and 0.64 mg salbutamol per day, respectively. The high dose salbutamol group had significantly more days alive and free of ALI than the low dose group (12.2 ± 4.4 days versus 7.6 ± 1.9 days, p = 0.02). There were no associations between dose of β agonist and non-pulmonary organ dysfunctions. High dose salbutamol (p = 0.04), APACHE II score (p = 0.02), and cause of ALI (p = 0.02) were independent variables associated with number of days alive and free of ALI in a multivariate linear regression model. Conclusion Our retrospective study suggests that salbutamol, an inhaled β2 agonist, is associated with a shorter duration and lower severity of ALI. A dose greater than 2.2 mg/day of inhaled salbutamol could be a minimal effective dose to evaluate in a randomized controlled trial.
Issue Date: 11-Jan-2006
Date of Acceptance: 15-Dec-2005
URI: http://hdl.handle.net/10044/1/60101
DOI: https://dx.doi.org/10.1186/cc3971
ISSN: 1364-8535
Publisher: BioMed Central
Journal / Book Title: Critical Care
Volume: 10
Issue: 1
Copyright Statement: © 2006 Manocha et al., licensee BioMed Central Ltd. This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.
Keywords: Science & Technology
Life Sciences & Biomedicine
Critical Care Medicine
General & Internal Medicine
RESPIRATORY-DISTRESS-SYNDROME
ALVEOLAR FLUID CLEARANCE
TUMOR-NECROSIS-FACTOR
METERED-DOSE INHALER
ADRENERGIC AGONISTS
LIQUID CLEARANCE
PULMONARY-EDEMA
VASCULAR-PERMEABILITY
NEBULIZED SALBUTAMOL
RECEPTOR STIMULATION
Administration, Inhalation
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adult
Aged
Aged, 80 and over
Albuterol
Female
Humans
Male
Middle Aged
Receptors, Adrenergic, beta-2
Respiration, Artificial
Respiratory Distress Syndrome, Adult
Retrospective Studies
11 Medical And Health Sciences
Emergency & Critical Care Medicine
Publication Status: Published
Article Number: R12
Online Publication Date: 2006-01-11
Appears in Collections:Division of Surgery
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx